Genetics and epigenetics of liver cancer

New Biotechnology

Volumn 30, Issue 4, 2013, Pages 381-384

  Ozen, Cigdem ^a   Yildiz, Gokhan ^a,b   Dagcan, Alper Tunga ^a   Cevik, Dilek ^a,b   Ors, Aysegul ^a,b   Keles, Umur ^a   Topel, Hande ^a   Ozturk, Mehmet ^a,b  

^a BILKENT UNIVERSITY   (Turkey)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC INFECTION; DNA HYPOMETHYLATION; HEPATOCELLULAR CARCINOMA; PRIMARY LIVER CANCERS; PROMOTER METHYLATION; REGULATORY GENES; THERAPEUTIC TARGETS; WHOLE GENOME ANALYSIS;

ALKYLATION; DISEASES; NUCLEIC ACIDS; VIRUSES;

GENE EXPRESSION;

AXIN1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; REGULATOR PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ARTICLE; CANCER GENETICS; CHROMOSOME ABERRATION; DNA METHYLATION; EPIGENETICS; GAIN OF FUNCTION MUTATION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOME ANALYSIS; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REGULATOR GENE; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; CARCINOMA, HEPATOCELLULAR; GENETIC EPIGENESIS; GENETICS; LIVER NEOPLASMS;

CARCINOMA, HEPATOCELLULAR; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; LIVER NEOPLASMS;

EID: 84877808348     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2013.01.007     Document Type: Article

References (35)

1. El-Serag H.B. Hepatocellular carcinoma. New England Journal of Medicine 2011, 365:1118-1127.
2. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273.e1.
3. El-Serag H.B., Marrero J.A., Rudolph L., Reddy K.R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763.
4. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255.
5. Buendia M.A. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Medical and Pediatric Oncology 2002, 39:530-535.
6. Guichard C., Amaddeo G., Imbeaud S., Ladeiro Y., Pelletier L., Maad I.B., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature Genetics 2012, 44:694-698.
7. Brechot C., Pourcel C., Louise A., Rain B., Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980, 286:533-535.
8. Brechot C., Gozuacik D., Murakami Y., Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Seminars in Cell Biology 2000, 10:211-231.
9. Fujimoto A., Totoki Y., Abe T., Boroevich K.A., Hosoda F., Nguyen H.H., et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nature Genetics 2012, 44:760-764.
10. Bressac B., Galvin K.M., Liang T.J., et al. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:1973-1977.
11. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Seminars in Liver Disease 1999, 19:235-242.
12. Ozturk M., Arslan-Ergul A., Bagislar S., Senturk S., Yuzugullu H. Senescence and immortality in hepatocellular carcinoma. Cancer Letters 2009, 286:103-113.
13. Huang J., Deng Q., Wang Q., Li K.Y., Dai J.H., Li N., et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nature Genetics 2012, 44:1117-1121.
14. Sandoval J., Esteller M. Cancer epigenomics: beyond genomics. Current Opinion in Genetics and Development 2012, 22:50-55.
15. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nature Medicine 2011, 17:330-339.
16. Pogribny I.P., Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Letters 2012, [Epub ahead of print].
17. Sceusi E.L., Loose D.S., Wray C.J. Clinical implications of DNA methylation in hepatocellular carcinoma. HPB (Oxford) 2011, 13:369-376.
18. Burchard J., Zhang C., Liu A.M., Poon R.T., Lee N.P., Wong K.F., et al. microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Molecular Systems Biology 2010, 6:402.
19. Lachenmayer A., Alsinet C., Savic R., Cabellos L., Toffanin S., Hoshida Y., et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clinical Cancer Research 2012, 18:4997-5007.
20. Murakami Y., Yasuda T., Saigo K., Urashima T., Toyoda H., Okanoue T., et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumourous tissues. Oncogene 2006, 25:2537-2545.
21. Cao R., Wang L., Wang H., Xia L., Xia L., Erdjument-Bromage H., Tempst P., et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002, 298:1039-1043.
22. Cai M.Y., Tong Z.T., Zheng F., Liao Y.J., Wang Y., Rao H.L., et al. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies. Gut 2011, 60:967-976.
23. Sasaki M., Ikeda H., Itatsu K., Yamaguchi J., Sawada S., Minato H., et al. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Laboratory Investigation 2008, 88:873-882.
24. Cheng A.S., Lau S.S., Chen Y., Kondo Y., Li M.S., Feng H., et al. EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis. Cancer Research 2011, 71:4028-4039.
25. Au S.L., Wong C.C., Lee J.M., Fan D.N., Tsang F.H., Ng I.O., et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumour suppressor microRNAs to promote liver cancer metastasis. Hepatology 2012, 56:622-631.
26. Yang F., Zhang L., Huo X.S., Yuan J.H., Xu D., Yuan S.X., et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumour growth through enhancer of zeste homolog 2 in humans. Hepatology 2011, 54:1679-1689.
27. Effendi K., Mori T., Komuta M., Masugi Y., Du W., Sakamoto M. Bmi-1 gene is upregulated in early-stage hepatocellular carcinoma and correlates with ATP-binding cassette transporter B1 expression. Cancer Science 2010, 101:666-672.
28. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Letters 2009, 280:168-176.
29. Wu L.M., Yang Z., Zhou L., Zhang F., Xie H.Y., Feng X.W., et al. Identification of histone deacetylase 3 as a biomarker for tumour recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS ONE 2010, 5:e14460.
30. Quint K., Agaimy A., Di Fazio P., Montalbano R., Steindorf C., Jung R., et al. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Archiv 2011, 459:129-139.
31. Xie H.J., Noh J.H., Kim J.K., Jung K.H., Eun J.W., Bae H.J., et al. HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS ONE 2012, 7:e34265.
32. Yuan J.H., Yang F., Chen B.F., Lu Z., Huo X.S., Zhou W.P., et al. The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology 2011, 54:2025-2035.
33. Choi M.S., Shim Y.H., Hwa J.Y., Lee S.K., Ro J.Y., Kim J.S., et al. Expression of DNA methyltransferases in multistep hepatocarcinogenesis. Human Pathology 2003, 34:11-17.
34. Saito Y., Kanai Y., Sakamoto M., Saito H., Ishii H., Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 2001, 33:561-568.
35. Li Y., Zhu Z., Zhang S., Yu D., Yu H., Liu L., et al. ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS ONE 2011, 6:e17794.